SYN News and Press, Synthetic Biologics Inc. From 11/04/19

Synthetic Biologics, Inc. (SYN) Q3 2019 Earnings Conference Call November 04, 2019, 16:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communications Steven Shallcross - CEO and CFO Michael Kaleko - SVP of Research and Development Vince Wacher - Head of Prod...

Synthetic Biologics (NYSEMKT: SYN ): Q3 GAAP EPS of -$0.31. More news on: Synthetic Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

ROCKVILLE, Md. , Nov. 4, 2019 /PRNewswire/ -- Synthetic Biologics, Inc.  (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provi...

ROCKVILLE, Md. , Oct. 28, 2019 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, annou...

In our most recent article, we focused on Iovance ( IOVA ), a cell therapy company that in our opinion has consistently generated positive data, has developed a commercializable product, and is deploying a de-risked clinical strategy for a clear unmet need. As a result, we saw nearly 100% ups...

ROCKVILLE, Md. , Sept. 26, 2019 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Offic...

Synthetic Biologics, Inc (SYN) Q2 2019 Earnings Conference Call August 08, 2019 04:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communication Steven Shallcross - Chief Executive Officer & Chief Financial Officer Vince Wacher - Head of Product & Corp...

Synthetic Biologics (NYSEMKT: SYN ): Q2 GAAP EPS of -$0.23. Cash and cash equivalents of $21.7M Shares  +3% Press Release More news on: Synthetic Biologics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,

ROCKVILLE, Md. , Aug. 8, 2019 /PRNewswire/ --  Synthetic Biologics, Inc.  (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reporte...

ROCKVILLE, Md. , Aug. 1, 2019 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its op...